Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis

Cytokine and Growth Factor Reviews

Volumn 24, Issue 5, 2013, Pages 443-453

  Zhang, Hong Liang ^a,b   Zheng, Xiang Yu ^b   Zhu, Jie ^a,b  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cytokine; Experimental autoimmune neuritis; Guillain Barr syndrome; T helper cell; Th17 cell

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; DISEASE CLASSIFICATION; DRUG TARGETING; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SHORT SURVEY; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH1 TH2 BALANCE; TH17 CELL; TH2 CELL;

ANIMALIA;

CYTOKINE; EXPERIMENTAL AUTOIMMUNE NEURITIS; GUILLAIN-BARRÉ SYNDROME; T HELPER CELL; TH17 CELL;

ANIMALS; CYTOKINES; GUILLAIN-BARRE SYNDROME; HUMANS; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 84884727759     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2013.05.005     Document Type: Short Survey

References (157)

1. Zhang H.L., Wu J., Zhu J. The role of apolipoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis. Journal of Biomedicine and Biotechnology 2010, 2010:357412.
2. Zhu Y., Bao L., Zhu S., Chen Z., van der Meide P., Nennesmo I., et al. CD4 and CD8 T cells, but not B cells, are critical to the control of murine experimental autoimmune neuritis. Experimental Neurology 2002, 177:314-320.
3. Lu M.O., Zhu J. The role of cytokines in Guillain-Barré syndrome. Journal of Neurology 2011, 258:533-548.
4. Guillain G., Barré J., Strohl A. Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquide cephalorachidien sans reaction cellulaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineux. Bulletins et Memoires Societe Medicale des Hopitaux de Paris 1916, 28:1462-1470.
5. van Doorn P.A., Ruts L., Jacobs B.C. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurology 2008, 7:939-950.
6. Hughes R.A., Cornblath D.R. Guillain-Barré syndrome. Lancet 2005, 366:1653-1666.
7. McKhann G.M., Cornblath D.R., Griffin J.W., Ho T.W., Li C.Y., Jiang Z., et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Annals of Neurology 1993, 33:333-342.
8. Feasby T.E., Hahn A.F., Brown W.F., Bolton C.F., Gilbert J.J., Koopman W.J. Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms?. Journal of the Neurological Sciences 1993, 116:185-192.
9. Drenthen J., Yuki N., Meulstee J., Maathuis E.M., van Doorn P.A., Visser G.H., et al. Guillain-Barré syndrome subtypes related to Campylobacter infection. Journal of Neurology, Neurosurgery and Psychiatry 2011, 82:300-305.
10. Hughes R.A., Hadden R.D., Gregson N.A., Smith K.J. Pathogenesis of Guillain-Barré syndrome. Journal of Neuroimmunology 1999, 100:74-97.
11. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). New England Journal of Medicine 1956, 255:57-65.
12. Sekiguchi Y., Uncini A., Yuki N., Misawa S., Notturno F., Nasu S., et al. Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: a Japanese-Italian collaborative study. Journal of Neurology, Neurosurgery and Psychiatry 2012, 83:23-28.
13. Chiba A., Kusunoki S., Shimizu T., Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Annals of Neurology 1992, 31:677-679.
14. Lehrich J.R., Arnason B.G. Suppression of experimental allergic neuritis in rats by prior immunization with nerve in saline. Acta Neuropathologica 1971, 18:144-149.
15. Rostami A., Gregorian S.K., Brown M.J., Pleasure D.E. Induction of severe experimental autoimmune neuritis with a synthetic peptide corresponding to the 53-78 amino acid sequence of the myelin P2 protein. Journal of Neuroimmunology 1990, 30:145-151.
16. Zou L.P., Ljunggren H.G., Levi M., Nennesmo I., Wahren B., Mix E., et al. P0 protein peptide 180-199 together with pertussis toxin induces experimental autoimmune neuritis in resistant C57BL/6 mice. Journal of Neuroscience Research 2000, 62:717-721.
17. Maurer M., Toyka K.V., Gold R. Immune mechanisms in acquired demyelinating neuropathies: lessons from animal models. Neuromuscular Disorders 2002, 12:405-414.
18. Hahn A.F., Feasby T.E., Gilbert J.J. Blood-nerve barrier studies in experimental allergic neuritis. Acta Neuropathologica 1985, 68:101-109.
19. Kieseier B.C., Seifert T., Giovannoni G., Hartung H.P. Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology 1999, 53:20-25.
20. Hartung H.P., Toyka K.V. T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome. Annals of Neurology 1990, (27 Suppl.):S57-S63.
21. Heusinkveld M., de Vos van Steenwijk P.J., Goedemans R., Ramwadhdoebe T.H., Gorter A., Welters M.J., et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. Journal of Immunology 2011, 187:1157-1165.
22. Kiefer R., Kieseier B.C., Stoll G., Hartung H.P. The role of macrophages in immune-mediated damage to the peripheral nervous system. Progress in Neurobiology 2001, 64:109-127.
23. Duan R.S., Jin T., Yang X., Mix E., Adem A., Zhu J. Apolipoprotein E deficiency enhances the antigen-presenting capacity of Schwann cells. Glia 2007, 55:772-776.
24. Hadden R.D., Gregson N.A., Gold R., Smith K.J., Hughes R.A. Accumulation of immunoglobulin across the 'blood-nerve barrier' in spinal roots in adoptive transfer experimental autoimmune neuritis. Neuropathology and Applied Neurobiology 2002, 28:489-497.
25. Zepp J., Wu L., Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends in Immunology 2011, 32:232-239.
26. Vriesendorp F.J., Flynn R.E., Malone M.R., Pappolla M.A. Systemic complement depletion reduces inflammation and demyelination in adoptive transfer experimental allergic neuritis. Acta Neuropathologica 1998, 95:297-301.
27. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. Journal of Immunology 1986, 136:2348-2357.
28. Coffman R.L. Origins of the T(H)1-T(H)2 model: a personal perspective. Nature Immunology 2006, 7:539-541.
29. Gigi E., Raptopoulou-Gigi M., Kalogeridis A., Masiou S., Orphanou E., Vrettou E., et al. Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease. Journal of Viral Hepatitis 2008, 15:145-154.
30. Martin-Fontecha A., Thomsen L.L., Brett S., Gerard C., Lipp M., Lanzavecchia A., et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nature Immunology 2004, 5:1260-1265.
31. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Reviews Immunology 2003, 3:133-146.
32. Mowen K.A., Glimcher L.H. Signaling pathways in Th2 development. Immunological Reviews 2004, 202:203-222.
33. Liew F.Y. T(H)1 and T(H)2 cells: a historical perspective. Nature Reviews Immunology 2002, 2:55-60.
34. Zhang H., Wu L.M., Wu J. Cross-talk between apolipoprotein E and cytokines. Mediators of Inflammation 2011, 2011:949072.
35. Nyati K.K., Prasad K.N., Rizwan A., Verma A., Paliwal V.K. TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barré syndrome. Archives of Neurology 2011, 68:445-452.
36. Lambracht-Washington D., Wolfe G.I. Cytokines in Guillain-Barré syndrome: a lesson in time. Archives of Neurology 2011, 68:427-428.
37. Zhu J., Bai X.F., Mix E., Link H. Cytokine dichotomy in peripheral nervous system influences the outcome of experimental allergic neuritis: dynamics of mRNA expression for IL-1 beta, IL-6, IL-10, IL-12, TNF-alpha, TNF-beta, and cytolysin. Clinical Immunology and Immunopathology 1997, 84:85-94.
38. Zhu J., Mix E., Link H. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. Journal of Neuroimmunology 1998, 84:40-52.
39. Bao L., Lindgren J.U., van der Meide P., Zhu S., Ljunggren H.G., Zhu J. The critical role of IL-12p40 in initiating, enhancing, and perpetuating pathogenic events in murine experimental autoimmune neuritis. Brain Pathology 2002, 12:420-429.
40. Deretzi G., Zou L.P., Pelidou S.H., Nennesmo I., Levi M., Wahren B., et al. Nasal administration of recombinant rat IL-4 ameliorates ongoing experimental autoimmune neuritis and inhibits demyelination. Journal of Autoimmunity 1999, 12:81-89.
41. Bai X.F., Zhu J., Zhang G.X., Kaponides G., Hojeberg B., van der Meide P.H., et al. IL-10 suppresses experimental autoimmune neuritis and down-regulates TH1-type immune responses. Clinical Immunology and Immunopathology 1997, 83:117-126.
42. Schmidt B., Stoll G., Hartung H.P., Heininger K., Schafer B., Toyka K.V. Macrophages but not Schwann cells express Ia antigen in experimental autoimmune neuritis. Annals of Neurology 1990, 28:70-77.
43. Jung S., Huitinga I., Schmidt B., Zielasek J., Dijkstra C.D., Toyka K.V., et al. Selective elimination of macrophages by dichlormethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis. Journal of the Neurological Sciences 1993, 119:195-202.
44. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Frontiers in Bioscience 2008, 13:453-461.
45. Gordon S. Alternative activation of macrophages. Nature Reviews Immunology 2003, 3:23-35.
46. Zhang Z., Zhang Z.Y., Schluesener H.J. Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. Journal of Immunology 2009, 183:3081-3091.
47. Infante-Duarte C., Horton H.F., Byrne M.C., Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. Journal of Immunology 2000, 165:6107-6115.
48. Doreau A., Belot A., Bastid J., Riche B., Trescol-Biemont M.C., Ranchin B., et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nature Immunology 2009, 10:778-785.
49. Aggarwal S., Ghilardi N., Xie M.H., de Sauvage F.J., Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. Journal of Biological Chemistry 2003, 278:1910-1914.
50. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. Journal of Experimental Medicine 2005, 201:233-240.
51. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
52. Hwang E.S. Transcriptional regulation of T helper 17 cell differentiation. Yonsei Medical Journal 2010, 51:484-491.
53. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008, 28:29-39.
54. Duvallet E., Semerano L., Assier E., Falgarone G., Boissier M.C. Interleukin-23: a key cytokine in inflammatory diseases. Annals of Medicine 2011, 43:503-511.
55. Leipe J., Grunke M., Dechant C., Reindl C., Kerzendorf U., Schulze-Koops H., et al. Role of Th17 cells in human autoimmune arthritis. Arthritis and Rheumatism 2010, 62:2876-2885.
56. Jadidi-Niaragh F., Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scandinavian Journal of Immunology 2011, 74:1-13.
57. Li S., Yu M., Li H., Zhang H., Jiang Y. IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome. Mediators of Inflammation 2012, 2012:260473.
58. Sakaguchi S., Ono M., Setoguchi R., Yagi H., Hori S., Fehervari Z., et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunological Reviews 2006, 212:8-27.
59. Braga M., Quecchia C., Cavallucci E., Di Giampaolo L., Schiavone C., Petrarca C., et al. T regulatory cells in allergy. International Journal of Immunopathology and Pharmacology 2011, 24:55S-64S.
60. Akdis M. Healthy immune response to allergens: T regulatory cells and more. Current Opinion in Immunology 2006, 18:738-744.
61. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
62. Takahashi T., Tagami T., Yamazaki S., Uede T., Shimizu J., Sakaguchi N., et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. Journal of Experimental Medicine 2000, 192:303-310.
63. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+ CD25- naive T cells to CD4+ CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. Journal of Experimental Medicine 2003, 198:1875-1886.
64. Harness J., McCombe P.A. Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain-Barré syndrome patients compared to controls. Journal of Clinical Neuroscience 2008, 15:1031-1035.
65. Chi L.J., Wang H.B., Zhang Y., Wang W.Z. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome. Journal of Neuroimmunology 2007, 192:206-214.
66. Louvet C., Kabre B.G., Davini D.W., Martinier N., Su M.A., DeVoss J.J., et al. A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy. Journal of Experimental Medicine 2009, 206:507-514.
67. Li X.L., Dou Y.C., Liu Y., Shi C.W., Cao L.L., Zhang X.Q., et al. Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells. Cellular Immunology 2011, 271:455-461.
68. Schoenborn J.R., Wilson C.B. Regulation of interferon-gamma during innate and adaptive immune responses. Advances in Immunology 2007, 96:41-101.
69. Pestka S., Kotenko S.V., Muthukumaran G., Izotova L.S., Cook J.R., Garotta G. The interferon gamma (IFN-gamma) receptor: a paradigm for the multichain cytokine receptor. Cytokine and Growth Factor Reviews 1997, 8:189-206.
70. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. Journal of Leukocyte Biology 2004, 75:163-189.
71. Hohnoki K., Inoue A., Koh C.S. Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. Journal of Neuroimmunology 1998, 87:27-32.
72. Csurhes P.A., Sullivan A.A., Green K., Pender M.P., McCombe P.A. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Neurology, Neurosurgery and Psychiatry 2005, 76:1431-1439.
73. Elkarim R.A., Dahle C., Mustafa M., Press R., Zou L.P., Ekerfelt C., et al. Recovery from Guillain-Barré syndrome is associated with increased levels of neutralizing autoantibodies to interferon-gamma. Clinical Immunology and Immunopathology 1998, 88:241-248.
74. Hartung H.P., Schafer B., van der Meide P.H., Fierz W., Heininger K., Toyka K.V. The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system. Annals of Neurology 1990, 27:247-257.
75. Zhu Y., Ljunggren H.G., Mix E., Li H.L., van der Meide P., Elhassan A.M., et al. Suppression of autoimmune neuritis in IFN-gamma receptor-deficient mice. Experimental Neurology 2001, 169:472-478.
76. Dahle C., Kvarnstrom M., Ekerfelt C., Samuelsson M., Ernerudh J. Elevated number of cells secreting transforming growth factor beta in Guillain-Barré syndrome. Acta Pathologica, Microbiologica, et Immunologica Scandinavica 2003, 111:1095-1104.
77. Press R., Deretzi G., Zou L.P., Zhu J., Fredman P., Lycke J., et al. IL-10 and IFN-gamma in Guillain-Barré syndrome. Network Members of the Swedish Epidemiological Study Group. Journal of Neuroimmunology 2001, 112:129-138.
78. Chu C.Q., Wittmer S., Dalton D.K. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. Journal of Experimental Medicine 2000, 192:123-128.
79. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunology 2005, 6:1123-1132.
80. Mao X.J., Zhang H.L., Zhu J. Tumor necrosis factor-alpha in experimental autoimmune neuritis. Neural Regeneration Research 2010, 5:70-78.
81. Chaparro M., Guerra I., Munoz-Linares P., Gisbert J.P. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2012.
82. Kassiotis G., Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. Journal of Experimental Medicine 2001, 193:427-434.
83. Stubgen J.P. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle and Nerve 2008, 37:281-292.
84. Zhang J., Dong H., Li B., Li C.Y., Guo L. Association of tumor necrosis factor polymorphisms with Guillain-Barré syndrome. European Neurology 2007, 58:21-25.
85. Wu L.Y., Zhou Y., Qin C., Hu B.L. The effect of TNF-alpha, FcgammaR and CD1 polymorphisms on Guillain-Barré syndrome risk: evidences from a meta-analysis. Journal of Neuroimmunology 2012, 243:18-24.
86. Radhakrishnan V.V., Sumi M.G., Reuben S., Mathai A., Nair M.D. Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome. Acta Neurologica Scandinavica 2004, 109:71-74.
87. Deng H., Yang X., Jin T., Wu J., Hu L.S., Chang M., et al. The role of IL-12 and TNF-alpha in AIDP and AMAN. European Journal of Neurology 2008, 15:1100-1105.
88. Sharief M.K., McLean B., Thompson E.J. Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome. Annals of Neurology 1993, 33:591-596.
89. Oka N., Akiguchi I., Kawasaki T., Mizutani K., Satoi H., Kimura J. Tumor necrosis factor-alpha in peripheral nerve lesions. Acta Neuropathologica 1998, 95:57-62.
90. Redford E.J., Hall S.M., Smith K.J. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain 1995, 118(Pt 4):869-878.
91. Said G., Hontebeyrie-Joskowicz M. Nerve lesions induced by macrophage activation. Research in Immunology 1992, 143:589-599.
92. Bao L., Lindgren J.U., Zhu Y., Ljunggren H.G., Zhu J. Exogenous soluble tumor necrosis factor receptor type I ameliorates murine experimental autoimmune neuritis. Neurobiology of Disease 2003, 12:73-81.
93. Zou L.P., Deretzi G., Pelidou S.H., Levi M., Wahren B., Quiding C., et al. Rolipram suppresses experimental autoimmune neuritis and prevents relapses in Lewis rats. Neuropharmacology 2000, 39:324-333.
94. Zhu J., Bai X.F., Hedlund G., Bjork J., Bakhiet M., Van Der Meide P.H., et al. Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses. Clinical and Experimental Immunology 1999, 115:56-63.
95. Smith C.A., Farrah T., Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994, 76:959-962.
96. Suvannavejh G.C., Lee H.O., Padilla J., Dal Canto M.C., Barrett T.A., Miller S.D. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cellular Immunology 2000, 205:24-33.
97. Lu M.O., Duan R.S., Quezada H.C., Chen Z.G., Mix E., Jin T., et al. Aggravation of experimental autoimmune neuritis in TNF-alpha receptor 1 deficient mice. Journal of Neuroimmunology 2007, 186:19-26.
98. Mao X.J., Zhang X.M., Zhang H.L., Quezada H.C., Mix E., Yang X., et al. TNF-alpha receptor 1 deficiency reduces antigen-presenting capacity of Schwann cells and ameliorates experimental autoimmune neuritis in mice. Neuroscience Letters 2010, 470:19-23.
99. Thalayasingam N., Isaacs J.D. Anti-TNF therapy. Best Practice & Research Clinical Rheumatology 2011, 25:549-567.
100. Lozeron P., Denier C., Lacroix C., Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Archives of Neurology 2009, 66:490-497.
101. Shin I.S., Baer A.N., Kwon H.J., Papadopoulos E.J., Siegel J.N. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis and Rheumatism 2006, 54:1429-1434.
102. Eguren C., Diaz Ley B., Dauden E., Garcia-Diez A., Losada M. Peripheral neuropathy in two patients with psoriasis in treatment with infliximab. Muscle and Nerve 2009, 40:488-489.
103. Cope A.P. Studies of T-cell activation in chronic inflammation. Arthritis Research 2002, 4(Suppl. 3):S197-S211.
104. Notley C.A., Inglis J.J., Alzabin S., McCann F.E., McNamee K.E., Williams R.O. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. Journal of Experimental Medicine 2008, 205:2491-2497.
105. Xu M., Mizoguchi I., Morishima N., Chiba Y., Mizuguchi J., Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clinical and Developmental Immunology 2010, 2010.
106. Watford W.T., Moriguchi M., Morinobu A., O'Shea J.J. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine and Growth Factor Reviews 2003, 14:361-368.
107. Del Vecchio M., Bajetta E., Canova S., Lotze M.T., Wesa A., Parmiani G., et al. Interleukin-12: biological properties and clinical application. Clinical Cancer Research 2007, 13:4677-4685.
108. Pelidou S.H., Zou L.P., Deretzi G., Nennesmo I., Wei L., Mix E., et al. Intranasal administration of recombinant mouse interleukin-12 increases inflammation and demyelination in chronic experimental autoimmune neuritis in Lewis rats. Scandinavian Journal of Immunology 2000, 51:29-35.
109. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
110. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annual Review of Immunology 2009, 27:485-517.
111. Lankford C.S., Frucht D.M. A unique role for IL-23 in promoting cellular immunity. Journal of Leukocyte Biology 2003, 73:49-56.
112. Goriely S., Neurath M.F., Goldman M. How microorganisms tip the balance between interleukin-12 family members. Nature Reviews Immunology 2008, 8:81-86.
113. Touil T., Fitzgerald D., Zhang G.X., Rostami A.M., Gran B. Pathophysiology of interleukin-23 in experimental autoimmune encephalomyelitis. Drug News & Perspectives 2006, 19:77-83.
114. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
115. Hu W., Dehmel T., Pirhonen J., Hartung H.P., Kieseier B.C. Interleukin 23 in acute inflammatory demyelination of the peripheral nerve. Archives of Neurology 2006, 63:858-864.
116. Sabat R. IL-10 family of cytokines. Cytokine and Growth Factor Reviews 2010, 21:315-324.
117. Sabat R., Grutz G., Warszawska K., Kirsch S., Witte E., Wolk K., et al. Biology of interleukin-10. Cytokine and Growth Factor Reviews 2010, 21:331-344.
118. O'Garra A., Barrat F.J., Castro A.G., Vicari A., Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunological Reviews 2008, 223:114-131.
119. Bashyam H. Th1/Th2 cross-regulation and the discovery of IL-10. Journal of Experimental Medicine 2007, 204:237.
120. Akdis C.A., Joss A., Akdis M., Faith A., Blaser K. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB Journal 2000, 14:1666-1668.
121. Taylor A., Akdis M., Joss A., Akkoc T., Wenig R., Colonna M., et al. IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1. Journal of Allergy and Clinical Immunology 2007, 120:76-83.
122. Myhr K.M., Vagnes K.S., Maroy T.H., Aarseth J.H., Nyland H.I., Vedeler C.A. Interleukin-10 promoter polymorphisms in patients with Guillain-Barré syndrome. Journal of Neuroimmunology 2003, 139:81-83.
123. Makowska A., Pritchard J., Sanvito L., Gregson N., Peakman M., Hayday A., et al. Immune responses to myelin proteins in Guillain-Barré syndrome. Journal of Neurology, Neurosurgery and Psychiatry 2008, 79:664-671.
124. Press R., Ozenci V., Kouwenhoven M., Link H. Non-T(H)1 cytokines are augmented systematically early in Guillain-Barré syndrome. Neurology 2002, 58:476-478.
125. Atkins S., Loescher A.R., Boissonade F.M., Smith K.G., Occleston N., O'Kane S., et al. Interleukin-10 reduces scarring and enhances regeneration at a site of sciatic nerve repair. Journal of the Peripheral Nervous System 2007, 12:269-276.
126. Paul W.E., Zhu J. How are T(H)2-type immune responses initiated and amplified?. Nature Reviews Immunology 2010, 10:225-235.
127. Nelms K., Keegan A.D., Zamorano J., Ryan J.J., Paul W.E. The IL-4 receptor: signaling mechanisms and biologic functions. Annual Review of Immunology 1999, 17:701-738.
128. Wurtz O., Bajenoff M., Guerder S. IL-4-mediated inhibition of IFN-gamma production by CD4+ T cells proceeds by several developmentally regulated mechanisms. International Immunology 2004, 16:501-508.
129. Le Gros G., Ben-Sasson S.Z., Seder R., Finkelman F.D., Paul W.E. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. Journal of Immunology 2008, 181:2943-2951.
130. Zheng W., Flavell R.A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997, 89:587-596.
131. Zhu J., Guo L., Watson C.J., Hu-Li J., Paul W.E. Stat6 is necessary and sufficient for IL-4's role in Th2 differentiation and cell expansion. Journal of Immunology 2001, 166:7276-7281.
132. Kaplan M.H., Schindler U., Smiley S.T., Grusby M.J. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996, 4:313-319.
133. Dahle C., Ekerfelt C., Vrethem M., Samuelsson M., Ernerudh J. T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barré syndrome. Journal of the Neurological Sciences 1997, 153:54-60.
134. Zhu J., Mix E., Issazadeh S., Link H. Dynamics of mRNA expression of interferon-gamma, interleukin 4 and transforming growth factor beta1 in sciatic nerves and lymphoid organs in experimental allergic neuritis. European Journal of Neurology 1996, 3:232-240.
135. Abbas N., Zou L.P., Pelidou S.H., Winblad B., Zhu J. Protective effect of Rolipram in experimental autoimmune neuritis: protection is associated with down-regulation of IFN-gamma and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous system. Autoimmunity 2000, 32:93-99.
136. Chen Y.C., Chen S.D., Miao L., Liu Z.G., Li W., Zhao Z.X., et al. Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. Journal of Neuroimmunology 2012, 243:56-60.
137. Olsen T., Rismo R., Cui G., Goll R., Christiansen I., Florholmen J. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine 2011, 56:633-640.
138. Brucklacher-Waldert V., Stuerner K., Kolster M., Wolthausen J., Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009, 132:3329-3341.
139. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. American Journal of Pathology 2008, 172:146-155.
140. Hofstetter H.H., Ibrahim S.M., Koczan D., Kruse N., Weishaupt A., Toyka K.V., et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cellular Immunology 2005, 237:123-130.
141. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. Journal of Immunology 2006, 177:566-573.
142. Zhang Z.Y., Zhang Z., Schluesener H.J. FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis. Neuropathology and Applied Neurobiology 2009, 35:487-495.
143. Zhang Z.Y., Zhang Z., Zug C., Nuesslein-Hildesheim B., Leppert D., Schluesener H.J. AUY954, a selective S1P(1) modulator, prevents experimental autoimmune neuritis. Journal of Neuroimmunology 2009, 216:59-65.
144. Pelidou S.H., Zou L.P., Deretzi G., Oniding C., Mix E., Zhu J. Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role. Experimental Neurology 2000, 163:165-172.
145. Burgess A.W., Metcalf D. The nature and action of granulocyte-macrophage colony stimulating factors. Blood 1980, 56:947-958.
146. Stanley E., Lieschke G.J., Grail D., Metcalf D., Hodgson G., Gall J.A., et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:5592-5596.
147. Fleetwood A.J., Cook A.D., Hamilton J.A. Functions of granulocyte-macrophage colony-stimulating factor. Critical Reviews in Immunology 2005, 25:405-428.
148. Codarri L., Gyulveszi G., Tosevski V., Hesske L., Fontana A., Magnenat L., et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nature Immunology 2011, 12:560-567.
149. Hamilton J.A. GM-CSF in inflammation and autoimmunity. Trends in Immunology 2002, 23:403-408.
150. McQualter J.L., Darwiche R., Ewing C., Onuki M., Kay T.W., Hamilton J.A., et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. Journal of Experimental Medicine 2001, 194:873-882.
151. Ponomarev E.D., Shriver L.P., Maresz K., Pedras-Vasconcelos J., Verthelyi D., Dittel B.N. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. Journal of Immunology 2007, 178:39-48.
152. Cook A.D., Braine E.L., Campbell I.K., Rich M.J., Hamilton J.A. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Research 2001, 3:293-298.
153. Sterman A.B., Schaumburg H.H., Asbury A.K. The acute sensory neuronopathy syndrome: a distinct clinical entity. Annals of Neurology 1980, 7:354-358.
154. Young R.R., Asbury A.K., Adams R.D., Corbett J.L. Pure pan-dysautonomia with recovery. Transactions of the American Neurological Association 1969, 94:355-357.
155. Suarez G.A., Fealey R.D., Camilleri M., Low P.A. Idiopathic autonomic neuropathy: clinical, neurophysiologic, and follow-up studies on 27 patients. Neurology 1994, 44:1675-1682.
156. Mori M., Kuwabara S., Fukutake T., Yuki N., Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001, 56:1104-1106.
157. Ropper A.H. Unusual clinical variants and signs in Guillain-Barré syndrome. Archives of Neurology 1986, 43:1150-1152.